

BLISS GVS PHARMA LIMITED

Regd. Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31.12.2011

(Rs. in Lakh)

| Sl. No. | PARTICULARS | QUARTER ENDED | | | 9 MONTHS ENDED | | YEAR ENDED |
|---------|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 31.12.2011 (UNAUDITED) | 30.09.2011 (UNAUDITED) | 31.12.2010 (UNAUDITED) | 31.12.2011 (UNAUDITED) | 31.12.2010 (UNAUDITED) | 31.03.2011 (AUDITED) |
| 1 | Sales/Income from Operations (Net) | 6373.22 | 7929.96 | 5111.67 | 19528.05 | 15867.33 | 21883.81 |
| 2 | Expenditure | | | | | | |
| | A) (Increase)/Decrease in Stock in Trade | -101.21 | -161.08 | -441.03 | 97.11 | -245.15 | -69.41 |
| | B) Consumption of Raw Materials | 3623.71 | 4439.01 | 2465.06 | 10425.35 | 7743.13 | 12027.84 |
| | C) Purchase of Traded Goods | 674.95 | 108.72 | 778.27 | 783.67 | 779.27 | 781.00 |
| | D) Employee Cost | 148.12 | 140.55 | 115.01 | 426.23 | 326.28 | 430.47 |
| | E) Depreciation / Amortisation | 0.75 | 143.34 | 147.50 | 299.09 | 440.25 | 546.95 |
| | F) Other Expenditure | 928.05 | 867.97 | 581.43 | 2302.11 | 1945.33 | 2841.35 |
| | G) Total | 5274.36 | 5538.51 | 3647.24 | 14334.57 | 10988.11 | 16558.20 |
| 3 | Profit from Operations Before | | | | | | |
| | Other Income Interest (1-2) | 1098.85 | 2391.45 | 1464.43 | 5193.48 | 4879.22 | 5325.61 |
| 4 | Other Income | 577.55 | 534.70 | 80.18 | 1188.60 | 94.92 | 187.27 |
| 5 | Profit Before Interest (3+4) | 1876.41 | 2926.15 | 1544.61 | 6382.08 | 4974.14 | 6512.88 |
| 6 | Interest | 69.33 | 73.23 | 57.52 | 218.62 | 146.29 | 214.74 |
| 7 | Profit After Interest But Before Tax (5-6) | 1607.08 | 2852.92 | 1487.09 | 6163.45 | 4827.85 | 6298.14 |
| 8 | Exceptional Items | - | - | - | - | - | - |
| 9 | Profit Before Tax (7-8) | 1607.08 | 2852.92 | 1487.09 | 6163.45 | 4827.85 | 6298.14 |
| 10 | Tax Expense (Including Deferred Tax) | 721.70 | 580.59 | 126.83 | 1647.24 | 531.06 | 1235.11 |
| 11 | Net Profit After Tax (9-10) | 885.38 | 2272.33 | 1360.26 | 4516.22 | 4296.79 | 4063.03 |
| 12 | Paid - Up Equity Capital | 1031.47 | 1031.47 | 1031.47 | 1031.47 | 1031.47 | 1031.47 |
| 13 | Reserves Excluding Revaluation Reserve (As Per Balance Sheet) | | | | | | |
| 14 | Reserve and Dividend (not Annualised) | 0.86 | 2.20 | 1.32 | 4.36 | 4.17 | 3.94 |
| 15 | Aggregate of Non-promoter Shareholding | | | | | | |
| | - No. of Shares (Face Value Rs.1/- Each) | 36187842 | 36187842 | 37513634 | 36187842 | 37513634 | 37300583 |
| | - Percentage of Shareholding (%) | 35.08 | 35.08 | 36.37 | 35.08 | 36.37 | 36.16 |
| 16 | Promoter and Promoter Group Shareholding | | | | | | |
| | A) Pledge/ Encumbered | | | | | | |
| | - No. of Shares (Face Value Rs.1/- Each) | - | - | - | - | - | - |
| | - Percentage of Shares (as % of the Total Shareholding of Promoter & Promoter Group) | - | - | - | - | - | - |
| | - Percentage of Shares (as % of the Total Share Capital of the Company) | - | - | - | - | - | - |
| | B) Non - Encumbered | | | | | | |
| | - No. of Shares (Face Value Rs.1/- Each) | 66958830 | 66958830 | 65699038 | 66958830 | 65633038 | 65845089 |
| | - Percentage of Shares (as % of the Total Shareholding of Promoter & Promoter Group) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| | - Percentage of Shares (As % of the Total Share Capital of the Company) | 64.92 | 64.92 | 63.63 | 64.92 | 63.63 | 63.84 |

NET SALES UP BY
₹ 3660.72
23.07%

PBT UP BY

₹ 1335.60
27.66%

EPS

₹ 4.38

Notes: 1. The company operates primarily in the Pharmaceutical Business and Hence has only one reportable segment.
2. In view of the extant volatility in exchange rates and considering longer duration of exports receivables, Unrealised Exchange Gains Aggregating to Rs. 411 lakhs which would have been reported on such exports receivables at the closing rate is not accounted for in the above Interim Financial Statements. The same will be recognised in the books on actual settlement or at the Year end which ever is earlier. The Statutory Auditors have brought this fact to the notice in their Limited Review report.
3. During the year, the company has invested in 50,000 Equity Shares of USD 1 each of Bliss GVS International Pte. Limited, its wholly owned subsidiary.
4. Previous period figures have been Regrouped / Rearranged wherever necessary.
5. During the quarter, 2 complaints were received and resolved, there were no complaints pending at the beginning and at the end of the quarter.
6. The above results were reviewed by the Audit Committee & were there after approved by the Board at its meeting held on February 06th, 2012
7. The Statutory Auditors have carried out "Limited Review" of the aforesaid results.

Place : Mumbai
Date : 6th February, 2012

FOR BLISS GVS PHARMA LIMITED
SD/-
S. N. KAMATH
MANAGING DIRECTOR